Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Significant cost savings achieved by in-sourcing urine drug testing for monitoring medication compliance in pain management.

Melanson SE, Tanasijevic MJ, Snyder ML, Darragh A, Quade C, Jarolim P.

Clin Chim Acta. 2013 Jun 25;422:10-4. doi: 10.1016/j.cca.2013.03.010. Epub 2013 Mar 29.

PMID:
23545276
2.

Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse.

McCarberg BH.

Postgrad Med. 2011 Nov;123(6):132-9. doi: 10.3810/pgm.2011.11.2503. Review.

PMID:
22104462
3.
4.

Optimizing urine drug testing for monitoring medication compliance in pain management.

Melanson SE, Ptolemy AS, Wasan AD.

Pain Med. 2013 Dec;14(12):1813-20. doi: 10.1111/pme.12207. Epub 2013 Jul 30.

PMID:
23899241
7.

A new automated urine fentanyl immunoassay: technical performance and clinical utility for monitoring fentanyl compliance.

Snyder ML, Jarolim P, Melanson SE.

Clin Chim Acta. 2011 May 12;412(11-12):946-51. doi: 10.1016/j.cca.2011.01.029. Epub 2011 Jan 31.

PMID:
21281622
9.

Improved detection of opioid use in chronic pain patients through monitoring of opioid glucuronides in urine.

Dickerson JA, Laha TJ, Pagano MB, O'Donnell BR, Hoofnagle AN.

J Anal Toxicol. 2012 Oct;36(8):541-7. doi: 10.1093/jat/bks063. Epub 2012 Jul 24.

PMID:
22833646
10.

Urine drug testing for pain management.

Magnani B, Kwong T.

Clin Lab Med. 2012 Sep;32(3):379-90. doi: 10.1016/j.cll.2012.07.001. Review.

PMID:
22939297
11.

Pathology consultation on urine compliance testing and drug abuse screening.

Ward MB, Hackenmueller SA, Strathmann FG; Education Committee of the Academy of Clinical Laboratory Physicians and Scientists.

Am J Clin Pathol. 2014 Nov;142(5):586-93. doi: 10.1309/AJCPZ0DS4QLYNCQG. Review.

PMID:
25319972
12.

Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs.

Heltsley R, DePriest A, Black DL, Robert T, Marshall L, Meadors VM, Caplan YH, Cone EJ.

J Anal Toxicol. 2011 Oct;35(8):529-40.

PMID:
22004671
13.

Determination of medication cutoff values in a pain patient population.

Pesce A, West C, West R, Crews B, Mikel C, Rosenthal M, Almazon P, Latyshev S.

J Opioid Manag. 2011 Mar-Apr;7(2):117-22.

PMID:
21561035
14.

A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management.

McCarberg BH.

Postgrad Med. 2011 Nov;123(6):124-31. doi: 10.3810/pgm.2011.11.2502. Review.

PMID:
22104461
15.

Observation of improved adherence with frequent urine drug testing in patients with pain.

Yee DA, Hughes MM, Guo AY, Barakat NH, Tse SA, Ma JD, Best BM, Atayee RS.

J Opioid Manag. 2014 Mar-Apr;10(2):111-8. doi: 10.5055/jom.2014.0200.

PMID:
24715666
16.

Evaluation of high-resolution mass spectrometry for urine toxicology screening in a pain management setting.

Crews BO, Pesce AJ, West R, Nguyen H, Fitzgerald RL.

J Anal Toxicol. 2012 Nov-Dec;36(9):601-7. doi: 10.1093/jat/bks071. Epub 2012 Sep 19.

PMID:
22995480
17.

Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in pain management population.

West R, Pesce A, West C, Crews B, Mikel C, Almazan P, Rosenthal M, Latyshev S.

Pain Physician. 2010 Jan-Feb;13(1):71-8.

19.

Effect of tramadol use on three point-of-care and one instrument-based immunoassays for urine buprenorphine.

Shaikh S, Hull MJ, Bishop KA, Griggs DA, Long WH, Nixon AL, Flood JG.

J Anal Toxicol. 2008 Jun;32(5):339-43.

PMID:
18544218
20.

Cost-benefit and cost-savings analyses of antiarrhythmic medication monitoring.

Snider M, Carnes C, Grover J, Davis R, Kalbfleisch S.

Am J Health Syst Pharm. 2012 Sep 15;69(18):1569-73. doi: 10.2146/ajhp110270.

PMID:
22935939

Supplemental Content

Support Center